These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33382581)

  • 41. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
    Glue P; Fang JW; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S
    Clin Pharmacol Ther; 2000 Nov; 68(5):556-67. PubMed ID: 11103758
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lipidization of human interferon-alpha: a new approach toward improving the delivery of protein drugs.
    Yuan L; Wang J; Shen WC
    J Control Release; 2008 Jul; 129(1):11-7. PubMed ID: 18448186
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pegylated protein encapsulated multivesicular liposomes: a novel approach for sustained release of interferon alpha.
    Vyas SP; Rawat M; Rawat A; Mahor S; Gupta PN
    Drug Dev Ind Pharm; 2006 Jul; 32(6):699-707. PubMed ID: 16885125
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b.
    Youngster S; Wang YS; Grace M; Bausch J; Bordens R; Wyss DF
    Curr Pharm Des; 2002; 8(24):2139-57. PubMed ID: 12369859
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Liver targeting of interferon through pullulan conjugation.
    Xi K; Tabata Y; Uno K; Yoshimoto M; Kishida T; Sokawa Y; Ikada Y
    Pharm Res; 1996 Dec; 13(12):1846-50. PubMed ID: 8987082
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multivalent antiviral XTEN-peptide conjugates with long in vivo half-life and enhanced solubility.
    Ding S; Song M; Sim BC; Gu C; Podust VN; Wang CW; McLaughlin B; Shah TP; Lax R; Gast R; Sharan R; Vasek A; Hartman MA; Deniston C; Srinivas P; Schellenberger V
    Bioconjug Chem; 2014 Jul; 25(7):1351-9. PubMed ID: 24932887
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.
    Bailon P; Palleroni A; Schaffer CA; Spence CL; Fung WJ; Porter JE; Ehrlich GK; Pan W; Xu ZX; Modi MW; Farid A; Berthold W; Graves M
    Bioconjug Chem; 2001; 12(2):195-202. PubMed ID: 11312680
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS).
    Foser S; Schacher A; Weyer KA; Brugger D; Dietel E; Marti S; Schreitmüller T
    Protein Expr Purif; 2003 Jul; 30(1):78-87. PubMed ID: 12821324
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity.
    Monkarsh SP; Ma Y; Aglione A; Bailon P; Ciolek D; DeBarbieri B; Graves MC; Hollfelder K; Michel H; Palleroni A; Porter JE; Russoman E; Roy S; Pan YC
    Anal Biochem; 1997 May; 247(2):434-40. PubMed ID: 9177709
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pegylated IFNs for chronic hepatitis C: an update.
    Grace MJ; Cutler DL; Bordens RW
    Expert Opin Drug Deliv; 2005 Mar; 2(2):219-26. PubMed ID: 16296749
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Pegylated interferons: preliminary review of their pharmacokinetic characteristics].
    Azanza Perea JR
    Rev Clin Esp; 2001 Apr; 201(4):205-12. PubMed ID: 11447908
    [No Abstract]   [Full Text] [Related]  

  • 52. Polyethylene Glycol-Like Brush Polymer Conjugate of a Protein Drug Does Not Induce an Antipolymer Immune Response and Has Enhanced Pharmacokinetics than Its Polyethylene Glycol Counterpart.
    Ozer I; Kelly G; Gu R; Li X; Zakharov N; Sirohi P; Nair SK; Collier JH; Hershfield MS; Hucknall AM; Chilkoti A
    Adv Sci (Weinh); 2022 Apr; 9(11):e2103672. PubMed ID: 35133079
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway.
    Grace MJ; Lee S; Bradshaw S; Chapman J; Spond J; Cox S; Delorenzo M; Brassard D; Wylie D; Cannon-Carlson S; Cullen C; Indelicato S; Voloch M; Bordens R
    J Biol Chem; 2005 Feb; 280(8):6327-36. PubMed ID: 15596441
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improvement of Site-Directed Protein-Polymer Conjugates: High Bioactivity and Stability Using a Soft Chain-Transfer Agent.
    Yang W; Zhu L; Cui Y; Wang H; Wang Y; Yuan L; Chen H
    ACS Appl Mater Interfaces; 2016 Jun; 8(25):15967-74. PubMed ID: 27284806
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of Polymer Bioconjugation on Protein Stability and Activity Investigated with Discrete Conjugates: Alternatives to PEGylation.
    Morgenstern J; Gil Alvaradejo G; Bluthardt N; Beloqui A; Delaittre G; Hubbuch J
    Biomacromolecules; 2018 Nov; 19(11):4250-4262. PubMed ID: 30222929
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic protein-polymer conjugates: advancing beyond PEGylation.
    Pelegri-O'Day EM; Lin EW; Maynard HD
    J Am Chem Soc; 2014 Oct; 136(41):14323-32. PubMed ID: 25216406
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Polymer selection impacts the pharmaceutical profile of site-specifically conjugated Interferon-α2a.
    Hauptstein N; Pouyan P; Wittwer K; Cinar G; Scherf-Clavel O; Raschig M; Licha K; Lühmann T; Nischang I; Schubert US; Pfaller CK; Haag R; Meinel L
    J Control Release; 2022 Aug; 348():881-892. PubMed ID: 35764249
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of the major positional isomer of pegylated interferon alpha-2b.
    Wang YS; Youngster S; Bausch J; Zhang R; McNemar C; Wyss DF
    Biochemistry; 2000 Sep; 39(35):10634-40. PubMed ID: 10978146
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nasal absorption of interferon: enhancement by surfactant agents.
    Baglioni C; Phipps RJ
    J Interferon Res; 1990 Oct; 10(5):497-504. PubMed ID: 2148759
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A brush-polymer conjugate of exendin-4 reduces blood glucose for up to five days and eliminates poly(ethylene glycol) antigenicity.
    Qi Y; Simakova A; Ganson NJ; Li X; Luginbuhl KM; Özer I; Liu W; Hershfield MS; Matyjaszewski K; Chilkoti A
    Nat Biomed Eng; 2016; 1():. PubMed ID: 28989813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.